Prostatype Genomics AB (PROGEN) Stock Statistics & Valuation Metrics

Prostatype Genomics AB has a market cap or net worth of kr82.57M. The enterprise value is kr12.73M.

Prostatype Genomics AB has 532,703,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Prostatype Genomics AB’s return on equity (ROE) is -1.68 and return on invested capital (ROIC) is -122.78%.

The current PE Ratio of Prostatype Genomics AB is ―. Prostatype Genomics AB’s PEG ratio is 0.00252.

In the last 12 months, Prostatype Genomics AB had revenue of 594.00K and earned -44.50M in profits. Earnings per share was -1.32.

In the last 12 months, operating cash flow was -23.80M and capital expenditures -258.00K, giving a free cash flow of -24.06M billion.

Prostatype Genomics AB pays an annual dividend of ―, resulting in a dividend yield of ―

Prostatype Genomics AB upcoming earnings date is Aug 31, 2026, TBA (Confirmed).

Prostatype Genomics AB as a current ratio of 0.44, with Debt / Equity ratio of 19.98%

In the past 12 months, Prostatype Genomics AB has paid 0.00 in taxes.

Prostatype Genomics AB EV to EBITDA ratio is -0.17, with an EV/FCF ratio of -0.26.

Prostatype Genomics AB has kr9.07M in cash and marketable securities with kr5.30M in debt, giving a net cash position of kr3.77M billion.

Gross margin is -3401.35%, with operating margin of -6579.12%, and net profit margin of -7492.09%.

The average price target for Prostatype Genomics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―